{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Polcaro G"],"funding":["PRIN"],"pagination":["63"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC10962156"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["23(1)"],"pubmed_abstract":["Efficient predictive biomarkers are needed for immune checkpoint inhibitor (ICI)-based immunotherapy in non-small cell lung cancer (NSCLC). Testing the predictive value of single nucleotide polymorphisms (SNPs) in programmed cell death 1 (PD-1) or its ligand 1 (PD-L1) has shown contrasting results. Here, we aim to validate the predictive value of PD-L1 SNPs in advanced NSCLC patients treated with ICIs as well as to define the molecular mechanisms underlying the role of the identified SNP candidate. rs822336 efficiently predicted response to anti-PD-1/PD-L1 immunotherapy in advanced non-oncogene addicted NSCLC patients as compared to rs2282055 and rs4143815. rs822336 mapped to the promoter/enhancer region of PD-L1, differentially affecting the induction of PD-L1 expression in human NSCLC ce"],"journal":["Molecular cancer"],"pubmed_title":["rs822336 binding to C/EBPβ and NFIC modulates induction of PD-L1 expression and predicts anti-PD-1/PD-L1 therapy in advanced NSCLC."],"pmcid":["PMC10962156"],"funding_grant_id":["2017-COD. 2017PHRC8X_003"],"pubmed_authors":["Liguori L","Giurato G","Piaz FD","Conti V","Cascella M","Nassa G","Ottaiano A","Donadio G","Sabbatino F","Manzo V","Langella M","Filippelli A","Polcaro G","Caputo A","Zeppa P","Chianese A","Corbi G","Col JD","Scognamiglio G","Dell'Annunziata F","De Marco M","Pepe S","Perri F","Franci G"],"additional_accession":[]},"is_claimable":false,"name":"rs822336 binding to C/EBPβ and NFIC modulates induction of PD-L1 expression and predicts anti-PD-1/PD-L1 therapy in advanced NSCLC.","description":"Efficient predictive biomarkers are needed for immune checkpoint inhibitor (ICI)-based immunotherapy in non-small cell lung cancer (NSCLC). Testing the predictive value of single nucleotide polymorphisms (SNPs) in programmed cell death 1 (PD-1) or its ligand 1 (PD-L1) has shown contrasting results. Here, we aim to validate the predictive value of PD-L1 SNPs in advanced NSCLC patients treated with ICIs as well as to define the molecular mechanisms underlying the role of the identified SNP candidate. rs822336 efficiently predicted response to anti-PD-1/PD-L1 immunotherapy in advanced non-oncogene addicted NSCLC patients as compared to rs2282055 and rs4143815. rs822336 mapped to the promoter/enhancer region of PD-L1, differentially affecting the induction of PD-L1 expression in human NSCLC ce","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Mar","modification":"2026-07-15T20:15:56.962Z","creation":"2026-07-09T03:10:46.763Z"},"accession":"S-EPMC10962156","cross_references":{"pubmed":["38528526"],"doi":["10.1186/s12943-024-01976-2"]}}